Abstract
Despite the fact that the etiopathogenesis of systemic lupus erythematosus is largely unknown, key steps in the pathophysiology of the disease have been recognized and targeted using gene therapy techniques. In animal models of lupus, gene transfer has been used to block the action of pro-inflammatory cytokines and co-stimulatory molecules leading to clinical improvement. In humans, ex vivo experiments have shown the feasibility of gene transfer in live T cells and its potential for restoring normal phenotype in T cells from patients with lupus. Still in experimental phase, gene therapy in lupus promises to correct the aberrant immunological response without the numerous side-effects of the currently used immunosuppressant medications.
Keywords: SLE, gene therapy, cytokines, cell therapy, genetics
Current Gene Therapy
Title: Gene Therapy in Systemic Lupus Erythematosus
Volume: 5 Issue: 6
Author(s): Vasileios C. Kyttaris, Petros P. Sfikakis, Yuang-Taung Juang and George C. Tsokos
Affiliation:
Keywords: SLE, gene therapy, cytokines, cell therapy, genetics
Abstract: Despite the fact that the etiopathogenesis of systemic lupus erythematosus is largely unknown, key steps in the pathophysiology of the disease have been recognized and targeted using gene therapy techniques. In animal models of lupus, gene transfer has been used to block the action of pro-inflammatory cytokines and co-stimulatory molecules leading to clinical improvement. In humans, ex vivo experiments have shown the feasibility of gene transfer in live T cells and its potential for restoring normal phenotype in T cells from patients with lupus. Still in experimental phase, gene therapy in lupus promises to correct the aberrant immunological response without the numerous side-effects of the currently used immunosuppressant medications.
Export Options
About this article
Cite this article as:
Kyttaris C. Vasileios, Sfikakis P. Petros, Juang Yuang-Taung and Tsokos C. George, Gene Therapy in Systemic Lupus Erythematosus, Current Gene Therapy 2005; 5 (6) . https://dx.doi.org/10.2174/156652305774964703
DOI https://dx.doi.org/10.2174/156652305774964703 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies
Current Medicinal Chemistry Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design Systemic Delivery of siRNA: Challenging but Promising
Recent Patents on Drug Delivery & Formulation Study of SARS-nCoV2 Indian Isolates Gaining Insights into Mutation Frequencies, Protein Stability and Prospective Effect on Pathogenicity
Coronaviruses Mechanisms and Immunological Roles of Apoptosis in Molluscs
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Extra Virgin Olive Oils Polyphenols: Biological Activities
Current Pharmaceutical Design New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy
Current Pharmaceutical Design Present Situation of the Development of Cellular-Type Hemoglobin-Based Oxygen Carrier (Hemoglobin-Vesicles)
Current Drug Discovery Technologies Intracellular Redox State as Target for Anti-Influenza Therapy: Are Antioxidants Always Effective?
Current Topics in Medicinal Chemistry Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Comparative Study of Non-High Density Lipoproteins Cholesterol Level and Lipid Profile in Pre-Diabetic and Diabetic Patients
CNS & Neurological Disorders - Drug Targets Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry COX-2 Inhibition Versus Gastroprotection with Dual COX Inhibitors: An Evidence-Based Approach
Current Pharmaceutical Design Pathophysiology and Treatment of Nonfamilial Hyperparathyroidism
Recent Patents on CNS Drug Discovery (Discontinued) Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors
Current HIV Research